Novel GATA6 loss-of-function mutation responsible for familial atrial fibrillation

  • Authors:
    • Jian Li
    • Wei-Dong Liu
    • Zhong-Liang Yang
    • Yi-Qing Yang
  • View Affiliations

  • Published online on: July 18, 2012     https://doi.org/10.3892/ijmm.2012.1068
  • Pages: 783-790
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Atrial fibrillation (AF) is the most commonly sustained cardiac arrhythmia, and confers a substantially increased risk of morbidity and mortality. Increasing evidence has indicated that hereditary defects are implicated in AF. However, AF is genetically heterogeneous and the genetic etiology of AF in a significant portion of patients remains unclear. In this study, the entire coding sequence and splice junctions of the GATA6 gene, which encodes a zinc-finger transcription factor crucial for cardiogenesis, were sequenced in 140 unrelated patients with lone AF. The available relatives of the index patient carrying an identified mutation and 200 unrelated ethnically-matched healthy individuals used as the controls were genotyped. The functional characteristics of the mutant GATA6 were assessed in contrast to its wild-type counterpart using a luciferase reporter assay system. As a result, a novel heterozygous GATA6 mutation, p.G469V, was identified in a family with AF inherited in an autosomal dominant pattern. The mutation was absent in the 200 control individuals and the altered amino acid was completely conserved across species. Functional analysis demonstrated that the GATA6 mutation was associated with a significantly decreased transcriptional activity. The findings provide novel insight into the molecular mechanism involved in the pathogenesis of AF, as well as insight into potential therapies for the prevention and treatment of AF.

Introduction

Atrial fibrillation (AF) is the most common type of sustained cardiac arrhythmia, accounting for approximately 1/3 of hospitalizations for heart rhythm disorders (1). The prevalence of AF is approximately 1% in the general population, and is drastically increasing with advancing age, rising from approximately 0.1% in individuals younger than 55 years of age up to almost 10% in those aged 80 years and older (2). The lifetime risk of developing AF is estimated to be 25% for both men and women over 40 years of age (3). AF confers a substantially increased risk of morbidity and mortality. It increases the risk of stroke by 3- to 5-fold, causing a huge economic burden on the health care system and an adverse impact on the quality of life of patients (4). Compared to subjects with sinus rhythm, patients with AF have a 2-fold increased risk of mortality (5). Additionally, AF can also result in other complications, such as adverse hemodynamics, impaired cognitive function or dementia, congestive heart failure and tachycardia-induced cardiomyopathy (6). AF is frequently observed as a complication of various cardiac and systemic conditions, including hypertension, coronary artery disease, valvular heart disease, cardiomyopathies and metabolic disorders. Hence, AF is traditionally regarded as an acquired disorder (1). However, in 30–45% of AF patients, an underlying cause cannot be identified by routine procedures, and such AF is defined as ‘idiopathic’ or ‘lone’ (1), of which at least 15% of patients have a positive family history, so termed familial AF (7). Growing evidence has substantiated the familial aggregation of AF and an increased susceptibility to AF in the close relatives of patients with AF, highlighting the fact that genetic factors play a role in the pathogenesis of AF in a subset of cases (814). Studies on human and medical genetics have revealed multiple AF-related genes, including KCNQ1, KCNE2, SCN5A, KCNH2, KCNJ2, GJA5, KCNA5, KCNE3, KCNE5, NPPA, NUP155, SCN1B, SCN2B, SCN3B and GJA1 (1529). In addition, 4 chromosomal loci linked to AF have been mapped, although the AF-associated genes have not yet been discovered (3033). Nevertheless, AF is genetically heterogeneous and the genetic determinants for AF in most patients remain unknown (7).

Recently, there is increasing evidence indicating the essential role of several transcription factors, including NKX2-5 and GATA4 in normal cardiogenesis (3436), and mutations in NKX2–5 and GATA4 have been causally implicated in congenital cardiovascular abnormalities and AF (3744). GATA6 is another member of the GATA family, and its expression and function overlap with those of GATA4 during cardiac development, particularly in the regulation of target gene expression synergistically with NKX2–5 (36,45), which implies the potential association of functionally impaired GATA6 with AF.

In this study, in order to evaluate the prevalence of GATA6 mutations in patients with lone AF and characterize the mechanism by which mutated GATA6 predisposes to AF, the coding exons and exon/intron boundaries of GATA6 were sequenced in patients with lone AF in contrast to healthy individuals, and the functional characteristics of the mutant GATA6 were analyzed in comparison with its wild-type counterpart using a luciferase reporter assay system.

Materials and methods

Study participants

A total of 140 unrelated patients with lone AF were identified among the Han Chinese population. The controls were 200 ethnically-matched unrelated healthy individuals. Peripheral venous blood samples were prepared and clinical data including medical records, electrocardiogram and echocardiography reports were collected. The study subjects were clinically classified using a consistently applied set of definitions (7,43). Briefly, the diagnosis of AF was made by a standard 12-lead electrocardiogram demonstrating no P waves and irregular R-R intervals regardless of the clinical symptoms. Lone AF was defined as AF occurring in individuals <60 years of age without other cardiac or systemic diseases by physical examination, electrocardiogram, transthoracic echocardiogram, and extensive laboratory tests. Familial AF was defined as the presence of documented lone AF in 2 or more 1st- or 2nd-degree relatives. Relatives with AF occurring at any age in the setting of structural heart disease (hypertensive, ischemic, myocardial or valvular) were classified as ‘undetermined’ for having an inherited form of AF. The ‘undetermined’ classification was also used if the documentation of AF on an electrocardiogram tracing was lacking in relatives with symptoms consistent with AF (palpitations, dyspnea and light-headedness), or if a screening electrocardiogram and echocardiogram were not performed, irrespective of the symptoms. Relatives were classified as ‘unaffected’ if they were asymptomatic and had a normal electrocardiogram. Paroxysmal AF was defined as AF lasting for >30 sec that terminated spontaneously. Persistent AF was defined as AF lasting for >7 days and requiring either pharmacological therapy or electrical cardioversion for termination. AF that was refractory to cardioversion or that was allowed to continue was classified as permanent. The study protocol was reviewed and approved by the local institutional ethics committee and written informed consent was obtained from all participants prior to investigation.

Genetic studies

Genomic DNA from all participants was extracted from blood lymphocytes with the Wizard® Genomic DNA Purification kit (Promega, Madison, WI, USA). Initially, the whole coding sequence and splice junctions of the GATA6 gene were screened in 140 unrelated patients with lone AF. Subsequently, genotyping of GATA6 was performed in the available relatives of the index patient carrying an identified mutation and 200 ethnically-matched unrelated healthy individuals used as the controls. The referential genomic DNA sequence of GATA6 was derived from GenBank (accession no. NT_010966). With the help of online Primer 3 software (http://frodo.wi.mit.edu), the primer pairs used to amplify the coding exons (exons 2–7) and intron-exon boundaries of GATA6 by polymerase chain reaction (PCR) were designed as shown in Table I. PCR was carried out using HotStarTaq DNA Polymerase (Qiagen, Hilden, Germany) on a PE 9700 Thermal Cycler (Applied Biosystems, Foster City, CA, USA) with standard conditions and concentrations of reagents. Amplified products were purified with the QIAquick Gel Extraction kit (Qiagen). Both strands of each PCR product were sequenced with a BigDye® Terminator v3.1 Cycle Sequencing kit (Applied Biosystems) under an ABI PRISM 3130XL DNA Analyzer (Applied Biosystems). The sequencing primers were those designed previously for specific region amplifications. DNA sequences were viewed and analyzed with the DNA Sequencing Analysis Software v5.1 (Applied Biosystems). The variant was validated by resequencing of an independent PCR-generated amplicon from the subject and met our quality control threshold with a call rate exceeding 99%.

Table I

The intronic primers used to amplify the coding exons and exon-intron boundaries of GATA6.

Table I

The intronic primers used to amplify the coding exons and exon-intron boundaries of GATA6.

ExonForward primer (5′ to 3′)Reverse primer (5′ to 3′)Amplicon (bp)
2-aTTG, TTA, ACC, CGT, CGA, TCT, CCGCG, AGG, GTC, TGG, TAC, ATC, TC543
2-bTGC, TGT, TCA, CTG, ACC, TCG, ACCTG, GGA, GAG, TAG, GGG, AAG, C466
2-cCCG, ACA, GCC, CTC, CAT, ACGGAA, AAC, AGG, GCC, CGA, GTG539
3GGC, CAA, GGA, GAA, AAG, CTC, AGGTT, GGA, ACA, GCC, GGG, ACA, G485
4TCT, TGG, CCC, AGA, AAA, GTC, AGTCA, TTT, GCT, GAT, TCT, TTG, TAA, CTG387
5 and 6CTG, GGA, TTA, GAG, GCG, TGA, GCTTT, ACT, AGA, GAG, CAG, CCC, AGT473
7ATT, TCT, CCT, GCC, CTG, GGT, CTCTG, CAC, AAA, AGC, AGA, CAC, GA382
Alignment of multiple GATA6 protein sequences across species

The multiple GATA6 protein sequences across various species were aligned using the software ClustalW version 2.0 (an interactive program at http://www.ebi.ac.uk/Tools/msa/clustalw2/).

Plasmids and site-directed mutagenesis

The recombinant expression plasmid pcDNA3-hGATA6 was kindly provided by Dr Angela Edwards-Ghatnekar, from the Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA. The atrial natriuretic factor (ANF)-luciferase reporter gene, which contains the 2600-bp 5′-flanking region of the ANF gene, namely ANF(−2600)-Luc, was kindly provided by Dr Ichiro Shiojima, from the Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan. The identified mutation was introduced into the wild-type GATA6 using a QuikChange II XL Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA, USA) with a complementary pair of primers. The mutant was sequenced to confirm the desired mutation and to exclude any other sequence variations.

Reporter gene assays

HEK-293 cells were cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf serum. The ANF(−2600)-Luc reporter construct and an internal control reporter plasmid [pGL4.75 (hRluc/CMV), Promega] were used in transient transfection assays to examine the transcriptional activation function of the GATA6 mutant. HEK-293 cells were transfected with 0.4 μg of wild-type or mutant pcDNA3-hGATA6 expression vector, 0.4 μg of ANF(−2600)-Luc reporter construct, and 0.04 μg of pGL4.75 control reporter vector using PolyFect Transfection Reagent (Qiagen). For co-transfection experiments, 0.2 μg of wild-type pcDNA3-hGATA6, 0.2 μg of mutant pcDNA3-hGATA6, 0.4 μg of ANF(−2600)-Luc and 0.04 μg of pGL4.75 were used. Firefly luciferase and Renilla luciferase activities were measured with the Dual-Glo® luciferase assay system (Promega) 48 h after transfection. A minimum of 3 independent experiments were performed for wild-type and mutant GATA6.

Statistical analysis

Data are expressed as the means ± SD. Continuous variables were examined for normality of distribution and the Student’s unpaired t-test was used for the comparison of numeric variables between 2 groups. A comparison of the categorical variables between 2 groups was performed using Pearson’s χ2 test or Fisher’s exact test when appropriate. A two-tailed P-value <0.05 was considered to indicate a statistically significant difference.

Results

Characteristics of the study subjects

A total of 140 unrelated patients with lone AF and a cohort of 200 ethnically-matched unrelated healthy individuals used as the controls were recruited and clinically evaluated. None of them had overt traditional risk factors for AF. There were no significant differences between the patient and control groups in baseline characteristics including age, gender, body mass index, blood pressure, fasting blood glucose and serum lipid levels, left atrial dimension, left ventricular ejection fraction, heart rate at rest, as well as lifestyle (data not shown). At the time of the present study, 12 patients were also diagnosed with hypertension in accordance with the criterion that the average systolic or diastolic blood pressure (2 readings made after 5 min of rest in the sitting position) was ≥140 or ≥90 mm Hg, respectively, but at the time of the initial diagnosis of AF, their blood pressures were normal. The baseline clinical characteristics of the 140 patients with lone AF are summarized in Table II.

Table II

The baseline clinical characteristics of the 140 patients with lone atrial fibrillation.

Table II

The baseline clinical characteristics of the 140 patients with lone atrial fibrillation.

ParameterNo. or quantityPercentage or range
Male7856
Age at first diagnosis of atrial fibrillation (years)48.5621–59
Type of atrial fibrillation at presentation
  Paroxysmal9266
  Persistent3525
  Permanent139
Positive family history of atrial fibrillation4532
Underwent cardioversion5841
Cardiac pacemaker installed107
Resting heart rate (bpm)76.1448–162
Systolic blood pressure (mmHg)128.0492–138
Diastolic blood pressure (mmHg)82.3665–88
Body mass index (kg/m2)22.2420–24
Left atrial diameter (mm)37.9031–46
Left ventricular ejection fraction (%)6250–72
Fasting blood glucose (mmol/l)4.524–6
Total cholesterol (mmol/l)3.713–5
Triglycerides (mmol/l)1.241–2
Medications
  Amiodarone9669
  Aspirin3223
  Warfarin6446
  β-blocker2820
  Calcium channel blocker1712
  Digoxin3525
GATA6 mutation

Direct sequencing of the coding exons and exon-intron boundaries of the GATA6 gene was carried out after PCR amplification of genomic DNA from each of the 140 patients with lone AF. A heterozygous GATA6 mutation was identified in 1/140 unrelated patients, with a prevalence of approximately 1.71% for GATA6 mutation. Specifically, A substitution of T for G in the second nucleotide of codon 469 (c.1406G>T), predicting the transition of glycine (G) into valine (V) at amino acid 469 (p.G469V) was identified in a patient with a positive family history. A representative 12-lead electrocardiogram of the index patient with AF is recorded in Fig. 1. The sequence chromatograms showing the detected heterozygous GATA6 sequence mutation of c.406G>T compared with the corresponding control sequence are shown in Fig. 2. The missense mutation was not found in either the control population or reported in the SNP database (http://www.ncbi.nlm.nih.gov/SNP). Genetic scan of the available family members displayed that the mutation was present in all affected living family members, but absent in unaffected family members examined. Pedigree analysis demonstrated that the mutation cosegregated with AF transmitted in an autosomal dominant pattern in the family with complete penetrance. The pedigree structure of the family is illustrated in Fig. 3. The phenotypic characteristics and results of genetic screening of the affected family members are listed in Table III. Congenital atrial septal defect was confirmed by medical records of previous catheter-based repairs in 2 AF patients (II-3 and III-4), indicating that AF may share a common genetic origin with congenital heart disease.

Table III

Phenotypic characteristics and status of GATA6 mutation of the affected pedigree members.

Table III

Phenotypic characteristics and status of GATA6 mutation of the affected pedigree members.

Subject information
Phenotype
Electrocardiogram
Echocardiogram
Genotype
IdentityGenderAge at time of study (years)Age at diagnosis of AF (years)AF (classification)Heart rate (beats/min)QRS interval (ms)QTcLAD (mm)LVEF (%)GATA6 mutation (G469V)
I-2F7745Permanent67904414265±
II-2F5440Persistent871144523860±
II-3M5142Paroxysmal711004423658±
III-1M2828Paroxysmal66884383367±
III-4F2323Paroxysmal951164192965±

[i] AF, atrial fibrillation; F, female; M, male; QTc, corrected QT interval; LAD, left atrial dimension; LVEF, left ventricular ejection fraction; ±, heterozygous GATA6 mutation.

Alignment of multiple GATA6 protein sequences

A cross-species alignment of GATA6 protein sequences showed that the altered amino acid was completely conserved, as presented in Fig. 4, suggesting that the amino acid is functionally important.

Transcriptional activity of the GATA4 mutants

The transcriptional activation characterization of the mutated GATA6 in HEK-293 cells was examined using one of its direct cardiac downstream target genes, ANP, as a luciferase reporter, and the activity of the ANP promoter was presented as the fold activation of Firefly luciferase activity relative to Renilla luciferase activity. Equal amounts of wild-type (0.4 μg) and G469V-mutant GATA6 (0.4 μg) activated the ANP promoter by ∼11- and ∼2-fold, respectively. When the same amount of wild-type GATA4 (0.2 μg) was co-transfected with G469V-mutant GATA4 (0.2 μg), the induced activation of the ANP promoter was ∼6-fold. These results suggest that the GATA6 mutation has a significantly reduced activation activity compared with its wild-type counterpart (Fig. 5).

Discussion

In the present study, a novel heterozygous GTA6 mutation of p.G469V identified in a family with lone AF is reported. This missense mutation of GATA6 was present in all the affected family members examined but was absent in the unaffected family members available and 400 normal chromosomes from a matched control population. A cross-species alignment of multiple GATA6 protein sequences exhibited that the altered amino acid was completely conserved. Functional analysis demonstrated that the p.G469V mutation of GATA6 was associated with a significantly decreased transcriptional activity. Therefore, it is highly likely that functionally impaired GATA6 is involved in the pathogenesis of AF in this family. To our knowledge, this is the first description of the correlation between a GATA6 loss-of-function mutation and susceptibility to familial AF. These results expand the spectrum of GATA6 mutations linked to AF and provide significant insight into the molecular basis underlying AF.

GATA transcription factors are a group of DNA binding proteins characteristic of preferential binding to the consensus DNA sequence GATA of target gene promoters. The GATA family comprises 6 members (GATA1–GATA6), of which GATA4, GATA5 and GATA6 are expressed in various mesoderm and endoderm-derived tissues, particularly in the embryonic and adult heart (36). GATA6 maps to human chromosome 18q11.1–q11.2 by fluorescence in situ hybridization, which encodes a predicted 449-amino-acid protein (46). Functionally, GATA6 consists of 2 transcriptional activation domains (TADs), 2 adjacent zinc fingers (ZFs), and 1 nuclear localization signal (NLS). The 2 TADs are essential for the transcriptional activity of GATA6. The C-terminal ZF is required for DNA sequence recognition and binding to the consensus motif, while the N-terminal ZF is responsible for stability and sequence specificity of protein-DNA binding as well as the transcriptional activation by GATA factors. The majority of the protein-protein interactions of GATA factors are mediated by its C-terminal ZF. The NLS sequence is associated with the subcellular trafficking and distribution of GATA6 (36). The GATA6 mutation, p.G469V, identified in this study is located in the C-terminal ZF; therefore, it may be expected to exert influence on the transcriptional activation of GATA6 by interfering with the binding to the downstream target DNA.

It has been substantiated that GATA6 is an upstream regulator of multiple genes transcribed during embryogenesis and cardiac morphogenesis, including the genes that encode the atrial natriuretic peptide (ANP), brain natriuretic peptide, α-myosin heavy chain, β-myosin heavy chain and cardiac troponin C and I (36). Hence, the functional characteristics of the GATA6 mutations may be explored by analysis of the transcriptional activity of the ANP promoter in cells transfected with the GATA6 mutant in contrast to its wild-type counterpart. In this study, the functional effect of the novel p.G469V mutation of GATA6 identified in our familial AF patients was characterized by transcriptional activity assays and the results demonstrated a significantly decreased transcriptional activity on a downstream gene, consistent with the loss-of-function effects of other GATA6 mutations underlying congenital cardiovascular malformations on the transcriptional activity of the ANP promoter (47,48). These findings indicate that the haploinsufficiency or loss-of-function effect resulting from GATA6 mutations is potentially an important pathophysiological mechanism involved in AF, although the functional roles of the recently reported AF-related GATA6 mutations remain to be ascertained (49).

The findings that functionally compromised GATA6 confers susceptibility to AF may be partially ascribed to the abnormally developed pulmonary vein myocardium (5052). The pulmonary venous vessels are ensheathed by a layer of myocardium termed pulmonary myocardial sleeve, which has been demonstrated to be responsible for the initiation and perpetuation of AF by several potential arrhythmogenic mechanisms, including intrinsic pacemaker activity and properties facilitating re-entrance (5052). Genetic labeling lineage-tracing studies have shown that NKX2-5 is expressed in the atrial and pulmonary myocardium and is essential for the localized formation of the sinoatrial node during embryonic development. NKX2-5 can act as a suppressor of the sinoatrial node lineage gene program, which limits pacemaker activity to the sinus and atrioventricular node. When the NKX2-5 protein level was lowered in a hypomorphic model, the pulmonary cardiomyocytes switched to connexin40-negative, HCN4-positive cells, a nodal-like phenotype with pacemaker activity (51). In NKX2-5-deficient mouse embryos, HCN4 was activated in the entire embryonic heart tube, whereas connexin40 expression was lost, and the ectopic expression of pacemaker cells was observed throughout the heart tube (53). In humans, AF has been reported as an isolated phenotype or a part of compound phenotypes in patients harboring NKX2-5 mutations (40,54,55). Therefore, as a transcriptionally cooperative partner of NKX2-5, GATA6, when a loss-of-function mutation occurs, may conduce to the formation of the pulmonary myocardium sleeve and the shift of the pulmonary myocardium to a sinoatrial node-like phenotype by reducing the expression of NKX2-5, hence producing an atrial electrophysiological substrate favoring AF.

There are a large number of downstream genes transactivated by GATA6, and mutations in several target genes have been associated with AF, including β-myosin heavy chain, ANP and connexin40 (24,25,56–58). Therefore, it is highly likely for mutated GATA6 to predispose to AF by decreasing the expression of target genes.

Of note, congenital atrial septal defect was documented in 2 AF patients carrying the p.G469V mutation of GATA6. Similar to our current findings, congenital cardiac defects were previously confirmed in 3 AF patients carrying heterozygous GATA6 mutations, including atrial septal defect in 1 missense mutation (p.Q206P) carrier and ventricular septal defect in 2 truncation mutation (p.Y265X) carriers (49). These observations suggest that AF may share a common genetic origin with congenital heart disease.

In conclusion, the results from the present study link a novel mutation in the cardiac transcription factor, GATA6, to familial AF and provides novel insight into the molecular mechanism involved in AF, as well as insight into potential therapies for the prevention and treatment of this common type of arrhythmia.

Acknowledgements

We are indebted to participants for their dedication to the study. This study was supported in part by grants from the National Natural Science Fund of China (81070153 and 30570768), the National Basic Research Program of China (2010CB912604), the Personnel Development Foundation of Shanghai, China (2010019), the Key Program of Basic Research of Shanghai, China (10JC1414000, 10JC1414001 and 10JC1414002) and the Natural Science Fund of Shanghai, China (10ZR1428000).

References

1. 

V FusterLE RydénDS CannomHJ CrijnsAB CurtisKA EllenbogenJL HalperinGN KayJY Le HuezeyJE LoweAmerican College of Cardiology Foundation/American Heart Association Task Force2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelinesCirculation123e269e3672011

2. 

AS GoEM HylekKA PhillipsY ChangLE HenaultJV SelbyDE SingerPrevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) StudyJAMA28523702375200110.1001/jama.285.18.2370

3. 

DM Lloyd-JonesTJ WangEP LeipMG LarsonD LevyRS VasanRB D’AgostinoJM MassaroA BeiserPA WolfEJ BenjaminLifetime risk for development of atrial fibrillation: the Framingham Heart StudyCirculation11010421046200410.1161/01.CIR.0000140263.20897.4215313941

4. 

PA WolfRD AbbottWB KannelAtrial fibrillation as an independent risk factor for stroke: the Framingham StudyStroke22983988199110.1161/01.STR.22.8.9831866765

5. 

EJ BenjaminPA WolfRB D’AgostinoH SilbershatzWB KannelD LevyImpact of atrial fibrillation on the risk of death: the Framingham Heart StudyCirculation98946952199810.1161/01.CIR.98.10.9469737513

6. 

JW MagnaniM RienstraH LinMF SinnerSA LubitzDD McManusJ DupuisPT EllinorEJ BenjaminAtrial fibrillation: current knowledge and future directions in epidemiology and genomicsCirculation12419821993201110.1161/CIRCULATIONAHA.111.03967722042927

7. 

D DarbarKJ HerronJD BallewA JahangirBJ GershWK ShenSC HammillDL PackerTM OlsonFamilial atrial fibrillation is a genetically heterogeneous disorderJ Am Coll Cardiol4121852192200310.1016/S0735-1097(03)00465-012821245

8. 

PT EllinorDM YoergerJN RuskinCA MacRaeFamilial aggregation in lone atrial fibrillationHum Genet118179184200510.1007/s00439-005-0034-816133178

9. 

DO ArnarS ThorvaldssonTA ManolioG ThorgeirssonK KristjanssonH HakonarsonK StefanssonFamilial aggregation of atrial fibrillation in IcelandEur Heart J27708712200610.1093/eurheartj/ehi72716428254

10. 

MJ JunttilaMJ RaatikainenJS PerkiömäkiK HongR BrugadaHV HuikuriFamilial clustering of lone atrial fibrillation in patients with saddleback-type ST-segment elevation in right precordial leadsEur Heart J28463468200710.1093/eurheartj/ehl47417242012

11. 

IE ChristophersenLS RavnE Budtz-JoergensenA SkyttheS HaunsoeJH SvendsenK ChristensenFamilial aggregation of atrial fibrillation: a study in Danish twinsCirc Arrhythm Electrophysiol2378383200910.1161/CIRCEP.108.78666519808493

12. 

YQ YangXL ZhangXH WangHW TanHF ShiWY FangX LiuFamilial aggregation of lone atrial fibrillation in the Chinese populationIntern Med4923852391201010.2169/internalmedicine.49.413021088338

13. 

SA LubitzX YinJD FontesJW MagnaniM RienstraM PaiML VillalonRS VasanMJ PencinaD LevyAssociation between familial atrial fibrillation and risk of new-onset atrial fibrillationJAMA30422632269201010.1001/jama.2010.169021076174

14. 

CS FoxH PariseRB D’Agostino SrDM Lloyd-JonesRS VasanTJ WangD LevyPA WolfEJ BenjaminParental atrial fibrillation as a risk factor for atrial fibrillation in offspringJAMA29128512855200410.1001/jama.291.23.285115199036

15. 

YH ChenSJ XuS BendahhouXL WangY WangWY XuHW JinH SunXY SuQN ZhuangKCNQ1 gain-of-function mutation in familial atrial fibrillationScience299251254200310.1126/science.107777112522251

16. 

Y YangM XiaQ JinS BendahhouJ ShiY ChenB LiangJ LinY LiuB LiuIdentification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillationAm J Hum Genet75899905200410.1086/42534215368194

17. 

TM OlsonVV MichelsJD BallewSP ReynaML KarstKJ HerronSC HortonRJ RodehefferJL AndersonSodium channel mutations and susceptibility to heart failure and atrial fibrillationJAMA293447454200510.1001/jama.293.4.44715671429

18. 

K HongP BjerregaardI GussakR BrugadaShort QT syndrome and atrial fibrillation caused by mutation in KCNH2J Cardiovasc Electrophysiol16394396200510.1046/j.1540-8167.2005.40621.x15828882

19. 

M XiaQ JinS BendahhouY HeMM LarroqueY ChenQ ZhouY YangY LiuB LiuA Kir2.1 gain-of-function mutation underlies familial atrial fibrillationBiochem Biophys Res Commun33210121019200510.1016/j.bbrc.2005.05.05415922306

20. 

MH GollobDL JonesAD KrahnL DanisXQ GongQ ShaoX LiuJP VeinotAS TangAF StewartSomatic mutations in the connexin 40 gene (GJA5) in atrial fibrillationN Engl J Med35426772688200610.1056/NEJMoa05280016790700

21. 

TM OlsonAE AlekseevXK LiuS ParkLV ZingmanM BienengraeberS SattirajuJD BallewA JahangirA TerzicKv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillationHum Mol Genet1521852191200610.1093/hmg/ddl14316772329

22. 

A LundbyLS RavnJH SvendsenS HaunsSP OlesenN SchmittKCNE3 mutation V17M identified in a patient with lone atrial fibrillationCell Physiol Biochem214754200810.1159/00011374618209471

23. 

LS RavnY AizawaGD PollevickJ Hofman-BangJM CordeiroU DixenG JensenY WuE BurashnikovS HaunsoGain of function in IKs secondary to a mutation in KCNE5 associated with atrial fibrillationHeart Rhythm5427435200810.1016/j.hrthm.2007.12.01918313602

24. 

DM Hodgson-ZingmanML KarstLV ZingmanDM HeubleinD DarbarKJ HerronJD BallewM de AndradeJC Burnett JrTM OlsonAtrial natriuretic peptide frameshift mutation in familial atrial fibrillationN Engl J Med359158165200810.1056/NEJMoa070630018614783

25. 

X RenC XuC ZhanY YangL ShiF WangC WangY XiaB YangG WuIdentification of NPPA variants associated with atrial fibrillation in a Chinese GeneID populationClin Chim Acta411481485201010.1016/j.cca.2009.12.01920064500

26. 

X ZhangS ChenS YooS ChakrabartiT ZhangT KeC ObertiSL YongF FangL LiMutation in nuclear pore component NUP155 leads to atrial fibrillation and early sudden cardiac deathCell13510171027200810.1016/j.cell.2008.10.02219070573

27. 

H WatanabeD DarbarDW KaiserK JiramongkolchaiS ChopraBS DonahuePJ KannankerilDM RodenMutations in sodium channel beta1- and beta2-subunits associated with atrial fibrillationCirc Arrhythm Electrophysiol2268275200910.1161/CIRCEP.108.77918119808477

28. 

P WangQ YangX WuY YangL ShiC WangG WuY XiaB YangR ZhangFunctional dominant-negative mutation of sodium channel subunit gene SCN3B associated with atrial fibrillation in a Chinese GeneID populationBiochem Biophys Res Commun39898104201010.1016/j.bbrc.2010.06.04220558140

29. 

IL ThibodeauJ XuQ LiG LiuK LamJP VeinotDH BirnieDL JonesAD KrahnR LemeryParadigm of genetic mosaicism and lone atrial fibrillation: physiological characterization of a connexin 43-deletion mutant identified from atrial tissueCirculation122236244201010.1161/CIRCULATIONAHA.110.961227

30. 

R BrugadaT TapscottGZ CzernuszewiczAJ MarianA IglesiasL MontJ BrugadaJ GironaA DomingoLL BachinskiR RobertsIdentification of a genetic locus for familial atrial fibrillationN Engl J Med336905911199710.1056/NEJM1997032733613029070470

31. 

PT EllinorJT ShinRK MooreDM YoergerCA MacRaeLocus for atrial fibrillation maps to chromosome 6q14–16Circulation10728802883200312782570

32. 

C ObertiL WangL LiJ DongS RaoW DuQ WangGenome-wide linkage scan identifies a novel genetic locus on chromosome 5p13 for neonatal atrial fibrillation associated with sudden death and variable cardiomyopathyCirculation11037533759200410.1161/01.CIR.0000150333.87176.C7

33. 

PG VoldersQ ZhuC TimmermansPM EurlingsX SuYH ArensL LiRJ JongbloedM XiaLM RodriguezYH ChenMapping a novel locus for familial atrial fibrillation on chromosome10p11–q21Heart Rhythm44694752007

34. 

DL HuFK ChenYQ LiuYH ShengR YangXQ KongKJ CaoHT GuLM QianGATA-4 promotes the differentiation of P19 cells into cardiac myocytesInt J Mol Med26365372201020664952

35. 

BG BruneauThe developmental genetics of congenital heart diseaseNature451943948200810.1038/nature0680118288184

36. 

S PikkarainenH TokolaR KerkeläH RuskoahoGATA transcription factors in the developing and adult heartCardiovasc Res63196207200410.1016/j.cardiores.2004.03.02515249177

37. 

J WangM FangXY LiuYF XinZM LiuXZ ChenXZ WangWY FangX LiuYQ YangA novel GATA4 mutation responsible for congenital ventricular septal defectsInt J Mol Med28557564201121637914

38. 

XY LiuJ WangJH ZhengK BaiZM LiuXZ WangX LiuWY FangYQ YangInvolvement of a novel GATA4 mutation in atrial septal defectsInt J Mol Med281723201121373748

39. 

J WangYF XinXY LiuZM LiuXZ WangYQ YangA novel NKX2-5 mutation in familial ventricular septal defectInt J Mol Med27369375201121165553

40. 

I Gutierrez-RoelensL De RoyC OvaertT SluysmansK DevriendtHG BrunnerM VikkulaA novel CSX/NKX2-5 mutation causes autosomal-dominant AV block: are atrial fibrillation and syncopes part of the phenotype?Eur J Hum Genet1413131316200610.1038/sj.ejhg.520170216896344

41. 

LH BoldtMG PoschA PerrotM PolotzkiS RolfAS ParwaniM HuemerA WutzlerC OzcelikW HaverkampMutational analysis of the PITX2 and NKX2–5 genes in patients with idiopathic atrial fibrillationInt J Cardiol145316317201020022124

42. 

MG PoschLH BoldtM PolotzkiS RichterS RolfA PerrotR DietzC OzcelikW HaverkampMutations in the cardiac transcription factor GATA4 in patients with lone atrial fibrillationEur J Med Genet53201203201010.1016/j.ejmg.2010.03.00820363377

43. 

YQ YangMY WangXL ZhangHW TanHF ShiWF JiangXH WangWY FangX LiuGATA4 loss-of-function mutations in familial atrial fibrillationClin Chim Acta41218251830201110.1016/j.cca.2011.06.01721708142

44. 

JQ JiangFF ShenWY FangX LiuYQ YangNovel GATA4 mutations in lone atrial fibrillationInt J Mol Med2810251032201121874226

45. 

Y ZhangN RathS HannenhalliZ WangT CappolaS KimuraE Atochina-VassermanMM LuMF BeersEE MorriseyGATA and Nkx factors synergistically regulate tissue-specific gene expression and development in vivoDevelopment134189198200710.1242/dev.0272017164424

46. 

E SuzukiT EvansJ LowryL TruongDW BellJR TestaK WalshThe human GATA-6 gene: structure, chromosomal location, and regulation of expression by tissue-specific and mitogen-responsive signalsGenomics38283290199610.1006/geno.1996.06308975704

47. 

X LinZ HuoX LiuY ZhangL LiH ZhaoB YanY LiuY YangYH ChenA novel GATA6 mutation in patients with tetralogy of Fallot or atrial septal defectJ Hum Genet55662667201010.1038/jhg.2010.84

48. 

GF ZhengD WeiH ZhaoN ZhouYQ YangXY LiuA novel GATA6 mutation associated with congenital ventricular septal defectInt J Mol Med2910651071201222407241

49. 

YQ YangXH WangHW TanWF JiangWY FangX LiuPrevalence and spectrum of GATA6 mutations associated with familial atrial fibrillationInt J Cardiol155494496201210.1016/j.ijcard.2011.12.09122257684

50. 

M HaïssaguerreP JaïsDC ShahA TakahashiM HociniG QuiniouS GarrigueA Le MourouxP Le MétayerJ ClémentySpontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veinsN Engl J Med33965966619989725923

51. 

MT MommersteegNA BrownOW PrallC de Gier-de VriesRP HarveyAF MoormanVM ChristoffelsPitx2c and Nkx2–5 are required for the formation and identity of the pulmonary myocardiumCirc Res1019029092007

52. 

MT MommersteegVM ChristoffelsRH AndersonAF MoormanAtrial fibrillation: a developmental point of viewHeart Rhythm618181824200910.1016/j.hrthm.2009.07.01119726237

53. 

MT MommersteegWM HoogaarsOW PrallC de Gier-de VriesC WieseDE CloutVE PapaioannouNA BrownRP HarveyAF MoormanVM ChristoffelsMolecular pathway for the localized formation of the sinoatrial nodeCirc Res100354362200710.1161/01.RES.0000258019.74591.b317234970

54. 

Y WatanabeDW BensonS YanoT AkagiM YoshinoJC MurrayTwo novel frameshift mutations in NKX2.5 result in novel features including visceral inversus and sinus venosus type ASDJ Med Genet39807811200210.1136/jmg.39.11.80712414819

55. 

S PabstB WollnikE RohmannY HintzK GlänzerH VetterG NickenigC GrohéA novel stop mutation truncating critical regions of the cardiac transcription factor NKX2-5 in a large family with autosomal-dominant inherited congenital heart diseaseClin Res Cardiol973942200810.1007/s00392-007-0574-0

56. 

EJ GruverD FatkinGA DoddsJ KissloBJ MaronJG SeidmanCE SeidmanFamilial hypertrophic cardiomyopathy and atrial fibrillation caused by Arg663His beta-cardiac myosin heavy chain mutationAm J Cardiol8313H18H199910.1016/S0002-9149(99)00251-910750581

57. 

YQ YangX LiuXL ZhangXH WangHW TanHF ShiWF JiangWY FangNovel connexin40 missense mutations in patients with familial atrial fibrillationEuropace1214211427201010.1093/europace/euq27420650941

58. 

YQ YangXL ZhangXH WangHW TanHF ShiWF JiangWY FangX LiuConnexin40 nonsense mutation in familial atrial fibrillationInt J Mol Med26605610201020818502

Related Articles

Journal Cover

October 2012
Volume 30 Issue 4

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Li, J., Liu, W., Yang, Z., & Yang, Y. (2012). Novel GATA6 loss-of-function mutation responsible for familial atrial fibrillation. International Journal of Molecular Medicine, 30, 783-790. https://doi.org/10.3892/ijmm.2012.1068
MLA
Li, J., Liu, W., Yang, Z., Yang, Y."Novel GATA6 loss-of-function mutation responsible for familial atrial fibrillation". International Journal of Molecular Medicine 30.4 (2012): 783-790.
Chicago
Li, J., Liu, W., Yang, Z., Yang, Y."Novel GATA6 loss-of-function mutation responsible for familial atrial fibrillation". International Journal of Molecular Medicine 30, no. 4 (2012): 783-790. https://doi.org/10.3892/ijmm.2012.1068